Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGR-1505 in Mature B-Cell Malignancies
NCT05544019Phase 1Recruiting
- Sponsor
- Schrödinger
- Start
- Apr 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of SGR-1505 in mature B-cell neoplasm (MBCN), non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and 9 more, sponsored by Schrödinger. Primary endpoints: Adverse Events at 2 years and Dose Limiting Toxicity at 21 days. Started Apr 2023; status: recruiting.
02
Drugs
SGR-1505
03
Conditions
mature B-cell neoplasm (MBCN)non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)Waldenström macroglobulinemia (WM)extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT05544019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544019.